Jim Tananbaum
Founder of Foresite Capital Management
Jim Tananbaum
Founder of Foresite Capital Management
San Francisco, California
Overview
Work Experience
Founder and CEO
2010 - Current
Founder, CEO and managing director of a multi-stage healthcare and life sciences investment firm, and chief architect of its rigorous scientific and data-driven approach to investment analysis. Foresite Capital aims to address areas of great unmet clinical need over the long term by funding promising healthcare and life sciences businesses at all stages of their life cycles.
Co-Founder and Managing Director PVP2 & PVP3
2001 - 2010
$1B healthcare venture capital group focussed on series A financings.
Co-Founder and Chief Executive Officer
1997 - 2000
http://www.theravance.com/ and http://www.inva.com/
Partner
1994 - 1997
Built Healthcare Service Investment practice. Led investments in Amerigroup, Healtheon, CareSelect (through Intensiva), and Novamed.
Co-Founder. Board Member.
1991 - 1997
Founded GelTex while finishing my Harvard degree, running the firm out of my garage for the first year. I recruited co-founder Professor George Whitesides from the Harvard Chemistry Department. Their product, Renvela, has helped more patients with renal failure than almost any drug in the world since its conception in 1991. The GelTex team also conceived of Cholestogel, which helped patients with high cholesterol that could not take other cholesterol reducing products. GelTex was sold to Genzyme, which was bought by Sanofi.
Product Manager, Prilosec
1991 - 1993
Primary architect of Prilosec GP strategy. Developed marketing campaign around promoting the use of Prilosec on patients with symptoms that had been treated with H2 antagonists (the previous market leaders). Pioneered using physician identified perscription data to focus marketing campaign on MDs that were top anti-ulcer prescribers.
Education
mba
1989 - 1991
Doctor of Medicine (MD)
1985 - 1989
Doctoral Affiliation
1985 - 1989
BS, BSEE
1981 - 1985